Anti-Rheumatic Rx

      Palliative Care & Rheum - #ACR23 @RheumNow
      Consider Pall Care for Serious Illness: "high mortality risk & negati

      Eric Dein

      2 years ago
      Palliative Care & Rheum - #ACR23 @RheumNow Consider Pall Care for Serious Illness: "high mortality risk & negatively impacts function or QoL OR strains caregivers" - thats a lot of rheum pt @HopkinsBayview-led session, always pt-centric @kekuchinad @MymaAlbaydaMD @jhrheumatology https://t.co/1j4lrkb5Ra
      Clinical Year in Review at #ACR23
      By @philseo (@jhrheumatology)

      Review some of the most impactful scientific studies

      Mithu Maheswaranathan, MD

      2 years ago
      Clinical Year in Review at #ACR23 By @philseo (@jhrheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

      Dr. John Cush RheumNow

      2 years ago
      Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv
      ARTIC REWIND RCT 3 yrs csDMARD withdrawal

      38% 3yrs csDMARDs free remission vs. 80% stable dose gpe

      75% recovery after

      Aurelie Najm

      2 years ago
      ARTIC REWIND RCT 3 yrs csDMARD withdrawal 38% 3yrs csDMARDs free remission vs. 80% stable dose gpe 75% recovery after restart Rx progression 19% in half dose gpe More use bioDMARDs (18%) & GCs (50%) withdraw gpe Trends towards lower infections @RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
      Tapering ABA vs. stable dose ABA in RA

      No diff in DAS28 remission at 2 years

      But…

      Only in patients receiving conco

      Aurelie Najm

      2 years ago
      Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
      Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia

      Having the dual skill set act

      David Liew drdavidliew

      2 years ago
      Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics #ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5
      Complements & HCQ? (Prof Petri et al)

      Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole

      sheila

      2 years ago
      Complements & HCQ? (Prof Petri et al) Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4 Improving C3,C4; addtl benefit of HCQ? #ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb
      TM83 #ACR23 @RheumNow
      45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv
      Low Ca, & Phos, ALP 239.

      Eric Dein

      2 years ago
      TM83 #ACR23 @RheumNow 45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv Low Ca, & Phos, ALP 239. Nml Vit D, High PTH. DEXA: Osteoporosis FGF23 high PET/CT showed soft tissue density in nasal septum, few cortical breaks Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
      Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR
      Phase 2 Randomized (1:1), Double-blind, Ve

      Bella Mehta bella_mehta

      2 years ago
      Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR Phase 2 Randomized (1:1), Double-blind, Vehicle-Controlled Trial 318 pts, 57% F, age 64, Clinically and statistically significant pain relief for 14 weeks compared to vehicle @RheumNow #ACR23 #abstL04
      If we're to summarize the challenges to making for CAR-T therapy work in a given disease, this is it:

      Dr. Chyi-Song Hsi

      David Liew drdavidliew

      2 years ago
      If we're to summarize the challenges to making for CAR-T therapy work in a given disease, this is it: Dr. Chyi-Song Hsieh ⁦@WUSTL #ACR23 @RheumNow https://t.co/raoHtrJ25S
      Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow

      We get int

      Eric Dein

      2 years ago
      Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
      Read my article on ACR Plenaries: Changing the Practice of Rheumatology #ACR23 @ACRheum @RheumNow @uptoTate @Yuz6Yusof

      TheDaoIndex KDAO2011

      2 years ago
      Read my article on ACR Plenaries: Changing the Practice of Rheumatology #ACR23 @ACRheum @RheumNow @uptoTate @Yuz6Yusof @ericdeinmd https://t.co/ql851dVzAk
      acr_session2.jpeg
      Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
      2 years ago
      Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
      ACR Daily Recap - MONDAY
      2 years ago
      1-PJP prophylaxis or not in ANCA?
      2-MTX single dose or split dose?
      3-IL6 blocker early on in GCA/PMR?
      4-SGLT2 in DM/Lupu

      Nouf Al hemmadi

      2 years ago
      1-PJP prophylaxis or not in ANCA? 2-MTX single dose or split dose? 3-IL6 blocker early on in GCA/PMR? 4-SGLT2 in DM/Lupus nephritis? 5-Cervical cancer screening in Lupus? 6-TNF induced ILD? https://t.co/mzGXajmQqE @RheumNow , Daily recap #ACR23

      Catch up on Conference Podcasts

      ×